TransMedics Group (NASDAQ:TMDX) Receives Hold Rating from Needham & Company LLC

TransMedics Group (NASDAQ:TMDX)‘s stock had its “hold” rating reiterated by investment analysts at Needham & Company LLC in a research report issued to clients and investors on Wednesday,Benzinga reports.

Several other brokerages also recently commented on TMDX. Canaccord Genuity Group lowered their target price on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. JPMorgan Chase & Co. decreased their price objective on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a research note on Tuesday, October 29th. Robert W. Baird dropped their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research report on Wednesday. Piper Sandler decreased their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, Oppenheimer reiterated an “outperform” rating and set a $125.00 price target on shares of TransMedics Group in a report on Tuesday, December 3rd. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, TransMedics Group currently has an average rating of “Moderate Buy” and an average target price of $126.80.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $68.99 on Wednesday. The stock has a market cap of $2.32 billion, a price-to-earnings ratio of 73.39 and a beta of 2.06. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group has a fifty-two week low of $65.78 and a fifty-two week high of $177.37. The firm’s 50-day simple moving average is $101.87 and its 200 day simple moving average is $133.40.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). The company had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm’s quarterly revenue was up 63.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.12) EPS. As a group, research analysts anticipate that TransMedics Group will post 1 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the sale, the director now directly owns 732 shares in the company, valued at approximately $61,158.60. This represents a 90.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $9,457,269.06. This represents a 12.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 28,042 shares of company stock valued at $3,563,985. 7.00% of the stock is owned by insiders.

Institutional Investors Weigh In On TransMedics Group

Institutional investors have recently made changes to their positions in the stock. International Assets Investment Management LLC bought a new stake in shares of TransMedics Group during the 2nd quarter valued at $47,000. USA Financial Formulas bought a new stake in shares of TransMedics Group during the third quarter valued at about $55,000. Quarry LP increased its position in shares of TransMedics Group by 557.1% during the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after buying an additional 312 shares during the period. National Bank of Canada FI lifted its holdings in shares of TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after buying an additional 262 shares in the last quarter. Finally, Signaturefd LLC boosted its position in shares of TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after acquiring an additional 93 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.